Celon Pharma S.A.
CLN.WA
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.01B
Close$
$-10.93
158.4% downside
Current Fair Value
158.4% downsideOvervalued by 158.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.01 Billion |
|---|---|
| Enterprise Value | $1.10 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.47 |
| Beta | 0.63 |
| Outstanding Shares | 53,911,500 |
Return
| Return on Equity | 22.22% |
|---|---|
| Return on Assets | 15.10% |
| Return on Invested Capital | -5.25% |
Valuation & Multiples
| P/E Ratio | 8.9 |
|---|---|
| PEG | -134.45 |
| Price to Sales | 4.68 |
| Price to Book Ratio | 2.08 |
| Enterprise Value to Revenue | 5.08 |
| Enterprise Value to EBIT | -31.64 |
| Enterprise Value to Net Income | 9 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 0.26 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 16, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$62.75 M
Average shareholder expectationNext Earnings Call
Expected Date
November 18, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$54.18 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Celon Pharma S.A.
562 employees
CEO: Maciej Wieczorek Celon Pharma S.A. operates as a fully-integrated pharmaceutical firm, undertaking the investigation, development, production, and distribution of diverse medicinal formulations. Its business model is structured around two principal areas...